Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adoption of Novel Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

NCT06671314 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT06671314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06671314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adoption of Novel Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Lead sponsor
Novartis
Phase
Observational
Overall status
Completed
Start date
June 2, 2022
Completion date
October 31, 2022
Enrollment
42,494 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction, heart failure with reduced ejection fraction